CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple MyelomaSimon J. Harrison, Piers Blombery, Tamia Nguyen et al.|Blood|2023Cited by 99
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory MyelomaSimon J. Harrison, Piers Blombery, Cyrille Touzeau et al.|New England Journal of Medicine|2025Cited by 58
Identification of Healthy Donor Phenotypic and Functional Signatures That Predict Allogeneic, Hypoimmune CD19-Directed CAR T Cell PotencyDarin Salloum, Terry J. Fry, Jasmin Kristianto et al.|Blood|2023Cited by 0